Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-03-26
2004-07-27
Owens, Amelia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S441000
Reexamination Certificate
active
06767921
ABSTRACT:
The subject of the present invention is the various polymorphic forms of benzyl (S,S)-2-(2-acetylsulphanylmethyl-3-benzo[1,3]dioxol-5-ylpropionylamino)propionate, called hereinafter Fasidotril, and the methods for preparing them.
Fasidotril, benzyl (S,S)-2-(2-acetylsulphanylmethyl-3-benzo[1,3]dioxol-5-ylpropionylamino)propionate, may be prepared by applying the methods described in Patent EP 0,419,327 B1 or Patent FR 0014419 filed by Société Civile Bioprojet and has advantageous properties as a mixed inhibitor of the enzymes enkephalinase (EC 3.4.24.11) and angiotensin converting enzyme (EC 3.4.15.1; ACE). It is indeed known that enkephalinase is a peptidase which degrades in particular enkephalins. Methionine and leucine enkephalin are peptides which were discovered in the brain and which are endogenous ligands for the morphine receptor. Moreover, the atrial natriuretic factor (ANF) is an endogenous peptide which exerts vasorelaxing, diuretic and natriuretic effects which are potentially beneficial in the treatment of cardiovascular and renal conditions. ANF is a substrate for enkephalinase and inhibitors of this peptidase slow its degradation, increase its plasma level and induce antihypertensive, diuretic and natriuretic effects (Lecomte et al., Proc. Natl. Ac. Sci. USA 1989, 86:19:7580-4).
It is also known, for example from French Patent No. 2,623,498 filed in the name of the applicant, that some amino acid derivatives exert an inhibitory activity on the enzyme for converting angiotensin I to angiotensin II (ACE), angiotensin II being an active vasomotor substance considered as the agent responsible for various forms of hypertension. These compounds are therefore useful for the treatment of hypertension and of cardiac insufficiency.
It has been discovered that Fasidotril can exist in various polymorphic crystalline forms which differ from each other in their physical and spectroscopic properties, their zones of thermodynamic stability and their methods of preparation. Four of these novel forms are described below and will be designated as form I, form II, form III and form IV, respectively.
It is shown that among these four forms, forms I and II are stable at low and high temperature, respectively, while forms III and IV are unstable and can be easily converted to the stable form I or II depending on the operating conditions chosen.
It is also shown that it is possible to convert form I to form II and to convert form II to form I depending on the operating conditions chosen.
The various polymorphic forms of Fasidotril may be prepared by crystallization, at a temperature of between the freezing point of the solution and the boiling point of the mixture, from a solution of Fasidotril in a solvent chosen from saturated hydrocarbons (for example pentane, cyclohexane) or unsaturated hydrocarbons (for example toluene, xylene), alcohols (for example methanol, ethanol, 2-propanol), ethers (for example diisopropyl ether, diethyl ether), esters (for example ethyl acetate, isopropyl acetate), amides (for example dimethylformamide, N-methyl-pyrrolidone, dimethylacetamide), nitriles (for example acetonitrile), halogenated solvents (for example dichloromethane, dichloroethane, chlorobenzene), water or a mixture of these solvents. This crystallization may be spontaneous or triggered by slow or rapid cooling, addition of a solvent, of seed crystals consisting of crystallized Fasidotril or another solid product, evaporation or distillation of the solvent. Furthermore, the initial Fasidotril solution may contain other products, for example an isomer of Fasidotril.
In the case, for example, of the preparation by spontaneous crystallization, it is possible to obtain form I by choosing a temperature of less than 25° C., or form II by choosing a higher temperature, for example 50° C., and maintaining this temperature for a sufficient period.
The various stable polymorphic forms of Fasidotril may also be prepared by conversion from one stable or metastable form to another. This conversion may be carried out in solution or in suspension by optionally seeding with a solid form of Fasidotril. This operation is carried out at a temperature between the freezing point of the solvent and its boiling point, in a solvent chosen from saturated hydrocarbons (for example pentane, cyclohexane) or unsaturated hydrocarbons (for example toluene, xylene), alcohols (for example methanol, ethanol, isopropanol), ethers (for example diisopropyl ether, diethyl ether), esters (for example ethyl acetate, isopropyl acetate), amides (for example dimethylformamide, N-methylpyrrolidone, dimethylacetamide), nitriles (for example acetonitrile), water or a mixture of these solvents.
The various polymorphic forms of Fasidotril may be characterized by X-ray diffraction (see FIG. 4), by differential scanning calorimetry, by infrared, by NMR of the solid or by any other method known to persons skilled in the art.
Form I has a novel X-ray powder diffraction spectrum (measurement carried out on a Siemens D5005 diffractometer with a copper anticathode; the results are exploited with the Eva v 7.0 software) with the following characteristic lines (2 theta in °):
17.1; 17.6; 17.9; 18.1; 18.8; 19.5; 20.0; 21.3; 22.1; 23.3; 24.8; 25.0; 27.8
The differential scanning calorimetry spectrum at 2° C./min shows two maxima, one at 110.3° C., the other at 114.1° C. with enthalpies of 40.13 J/g and 65.47 J/g, respectively, and an onset of melting at 108.8° C.
The infrared spectrum as a KBr tablet has the characteristic absorptions at the following wavelengths (in cm
−1
, f for weak, m for average, F for strong):
3280 (F), 3080 (f), 3040 (f), 3000 (f), 2920 (m), 2800 (f), 1730 (F), 1690 (F), 1680 (F), 1640 (F), 1610 (f), 1540 (F), 1500 (F), 1480 (F), 1440 (F), 1400 (f), 1380 (m), 1360 (f), 1330 (m), 1310 (m), 1280 (m), 1260 (F), 1250 (F), 1220 (F), 1200 (F), 1130 (F), 1110 (F), 1060 (f), 1040 (F), 1010 (f), 1000 (f), 960 (F), 940 (f), 930 (m), 900 (m), 860 (f), 810 (m), 790 (m), 750 (F), 720 (f), 700 (F), 680 (f), 620 (F), 600 (f), 580 (f), 540 (f), 520 (f), 480 (f), 460 (f), 450 (f), 430 (f)
Form II has a novel X-ray powder diffraction spectrum (measurement carried out on a Siemens D5005 diffractometer with a copper anticathode; the results are exploited with the Eva v 7.0 software) with the following characteristic lines (2 theta in °):
8.1; 12.9; 16.2; 16.8; 17.3; 17.8; 18.4; 20.8; 23.8; 27.7
The differential scanning calorimetry spectrum at 2° C./min shows a maximum at 114.8° C. with an enthalpy of 101.64 J/g and an onset of melting at 112.6° C.
The infrared spectrum as a KBr tablet has the characteristic absorptions at the following wavelengths (in cm
−1
, f for weak, m for average, F for strong):
3320 (F), 3280 (F), 3080 (f), 3000 (f), 2920 (m), 2880 (m), 2800 (f), 1730 (F), 1690 (F), 1680 (F), 1640 (F), 1540 (F), 1500 (F), 1480 (F), 1440 (F), 1400 (f), 1380 (m), 1360 (m), 1330 (m), 1310 (m), 1280 (m), 1260 (F), 1220 (F), 1200 (F), 1160 (f), 1130 (F), 1110 (F), 1060 (f), 1040 (F), 1010 (f), 1000 (f), 960 (F), 940 (m), 930 (m), 900 (m), 860 (f), 810 (m), 790 (m), 750 (F), 700 (F), 620 (F), 600 (f), 580 (f), 540 (f), 520 (f), 480 (f), 460 (f), 430 (f).
Form III has a novel X-ray powder diffraction spectrum (measurement carried out on a Siemens D5005 diffractometer with a copper anticathode; the results are exploited with the Eva v 7.0 software) with the following characteristic lines (2 theta in °):
11.1; 12.2; 16.4; 16.7; 17.7; 17.9; 18.6; 19.1; 20.2; 20.6; 21.3; 22.2; 22.6; 24.2; 24.7; 26.8; 28.6
The differential scanning calorimetry spectrum at 0.2° C./min shows four maxima at 101.3° C., 103.6° C., 105.9° C. and 113.9° C. with enthalpies of 3.62 J/g, 3.92 J/g, 1.61 J/g and 94.08 J/g, respectively, and onsets at 100.7° C., 103.0° C., 104.8° C. and 112.1° C., respectively.
Form IV has a novel X-ray powder diffraction spectrum (measurement carried out on a Siemens D5005 diffractometer with a copper anticathode; the results are exploited with the Eva v 7.0 software) with the following characteristic lines (2 t
Capet Marc
Coquerel Gerard
Danvy Denis
Lecomte Jeanne-Marie
Petit Marie-Noëlle
Bioproject
Owens Amelia
Schulman B. Aaron
Stites & Harbison PLLC
LandOfFree
Polymorphic forms of fasidotril, their methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphic forms of fasidotril, their methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphic forms of fasidotril, their methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3225649